Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
6.48
Dollar change
+0.13
Percentage change
2.05
%
Index- P/E- EPS (ttm)-1.05 Insider Own37.14% Shs Outstand39.11M Perf Week10.77%
Market Cap276.96M Forward P/E- EPS next Y-1.59 Insider Trans0.00% Shs Float26.86M Perf Month1.89%
Income-37.37M PEG- EPS next Q-0.34 Inst Own49.15% Short Float1.61% Perf Quarter66.58%
Sales19.94M P/S13.89 EPS this Y-29.52% Inst Trans6.11% Short Ratio1.67 Perf Half Y191.89%
Book/sh2.85 P/B2.28 EPS next Y-16.62% ROA-22.30% Short Interest0.43M Perf Year159.20%
Cash/sh3.14 P/C2.06 EPS next 5Y3.90% ROE-31.98% 52W Range1.57 - 8.19 Perf YTD67.88%
Dividend Est.- P/FCF- EPS past 5Y-13.31% ROI-24.10% 52W High-20.92% Beta0.70
Dividend TTM- Quick Ratio7.14 Sales past 5Y5.40% Gross Margin87.77% 52W Low311.82% ATR (14)0.47
Dividend Ex-Date- Current Ratio7.14 EPS Y/Y TTM44.23% Oper. Margin-203.09% RSI (14)54.36 Volatility6.92% 6.82%
Employees47 Debt/Eq0.47 Sales Y/Y TTM21.60% Profit Margin-187.37% Recom1.00 Target Price12.60
Option/ShortYes / Yes LT Debt/Eq0.39 EPS Q/Q15.46% Payout- Rel Volume0.59 Prev Close6.35
Sales Surprise-22.78% EPS Surprise22.17% Sales Q/Q-79.39% EarningsMar 07 BMO Avg Volume258.68K Price6.48
SMA201.30% SMA508.26% SMA20078.60% Trades Volume152,707 Change2.05%
Date Action Analyst Rating Change Price Target Change
Aug-24-23Initiated Wedbush Outperform $9
Jun-06-23Resumed Jefferies Buy $11 → $12
Sep-10-21Initiated BofA Securities Buy $26
May-25-21Initiated SVB Leerink Outperform $29
May-25-21Initiated Jefferies Buy $22
May-25-21Initiated H.C. Wainwright Buy $32
May-25-21Initiated Evercore ISI Outperform $23
Mar-12-24 09:55AM
Mar-07-24 02:52PM
08:45AM
07:00AM
Mar-06-24 08:00AM
04:30PM Loading…
Mar-05-24 04:30PM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Nov-22-23 07:00AM
Nov-14-23 04:25PM
Nov-03-23 07:00AM
Oct-31-23 09:00AM
Oct-27-23 04:58AM
Sep-27-23 09:00AM
Sep-11-23 04:05PM
04:05PM Loading…
Sep-05-23 04:05PM
Aug-24-23 09:57AM
Aug-13-23 08:04AM
Aug-11-23 03:21PM
Aug-10-23 08:25AM
07:10AM
Jun-30-23 06:10AM
Jun-01-23 07:00AM
May-11-23 08:35AM
07:00AM
May-01-23 07:00AM
Apr-19-23 10:00AM
Mar-23-23 08:25AM
07:00AM
Mar-16-23 07:30AM
07:30AM Loading…
Mar-15-23 07:30AM
Feb-24-23 07:30AM
Feb-17-23 05:08AM
Feb-07-23 07:00AM
Jan-20-23 05:16AM
Dec-12-22 10:22AM
Nov-10-22 09:00AM
08:15AM
07:00AM
Nov-07-22 04:05PM
Sep-07-22 07:00AM
Sep-01-22 07:00AM
Aug-15-22 06:45AM
Aug-11-22 07:00AM
Aug-03-22 07:00AM
Jul-05-22 07:54AM
Jun-06-22 04:51PM
May-10-22 07:00AM
Apr-08-22 02:29PM
01:00PM
Apr-07-22 09:25AM
08:34AM
07:00AM
Mar-24-22 07:00AM
Mar-16-22 08:00AM
Mar-15-22 08:00AM
Feb-08-22 08:00AM
Jan-26-22 06:53AM
Jan-05-22 08:00AM
Dec-14-21 04:01PM
Dec-01-21 08:00AM
Nov-10-21 07:00AM
Nov-08-21 08:03AM
Oct-28-21 04:01PM
Oct-27-21 07:30AM
Sep-14-21 08:00AM
Sep-08-21 08:00AM
Aug-19-21 10:57AM
Aug-18-21 07:30AM
Aug-12-21 07:00AM
Jul-30-21 05:03AM
Jun-24-21 07:00AM
Jun-18-21 09:16PM
Jun-15-21 07:00AM
Jun-10-21 07:00AM
May-27-21 07:30AM
May-21-21 07:41PM
Apr-30-21 04:44PM
12:00PM
Apr-29-21 09:19PM
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.